

TAP Financial Partner Dr. Christopher Romig Named Clinical Network Director at TARA Mind

Dr. Romig is a pioneer in the use of ketamine therapy for individuals coping with a variety of mental health, chronic pain, and addiction issues.

SAN DIEGO, CALIFORNIA, USA, January 24, 2023 /EINPresswire.com/ -- Dr. Christopher Romig has been named clinical network director at TARA Mind, a platform that provides responsible, safe, and effective access to psychedelic therapy providers and resources. Romig, partner and medical director at Ark Integrative Medicine and Therapeutics, a principal investment of TAP Financial Partners, Ltd., is a pioneer in the use of ketamine therapy for individuals coping with a variety of mental health, chronic pain, and addiction issues.

TARA Mind was co-founded by Marcus Capone, a former Navy SEAL that also leads the nonprofit VETS: Veterans Exploring Treatment Options. Romig's role with the company will involve vetting clinics in the U.S. that provide psychedelic-assisted therapy to ensure they meet TARA Mind's standards for care.



Dr. Romig and Ark have done more than 5,000 ketamine infusions since 2016, incorporating it into an overall wellness plan to make lasting changes in the lives of patients that have been resistant to more traditional medical treatment regimens.



TAP is a principal investor in Ark Integrative Medicine and Therapeutics.

"Our goal with TARA Mind is to help

them create gold standards that veterans looking to psychedelics and psychotherapy can trust to overcome mental health issues," said Romig, a fellowship-trained anesthesiologist. "We're also hoping to release a comprehensive study in the time to come that further quantifies the positive



impact of these alternative treatments."

Our goal with TARA Mind is to help them create gold standards that veterans looking to psychedelics and psychotherapy can trust to overcome mental health issues."

Dr. Christopher Romig, CEO of ARK Integrative Medicine and Therapeutics Dr. Romig, a graduate of Duke and Emory universities, and Ark have done more than 5,000 ketamine infusions since 2016, incorporating it into an overall wellness plan to make lasting changes in the lives of patients that have been resistant to more traditional medical treatment regimens. His patients have seen as much as 75% improvement in baseline scoring of symptoms for depression, anxiety, chronic pain, and post-traumatic stress disorder (PTSD).

Romig tailors his therapy to the specific needs of his patients, with up to six infusions of ketamine-based

medication given in a two-week period and additional boosters sometimes required. Individuals suffering from depression, anxiety, PTSD, bi-polar disorder, fibromyalgia, neuropathy, alcohol, and drug addiction have all been helped through this approach.

TAP, as a founding investor in Ark, have aligned their interests with Dr. Romig and will soon be announcing the opening of a clinic in Tampa, with expansion to London also part of its strategic plan.

###

TAP Financial Partners is a privately-held, boutique merchant bank providing advisory, restructuring, debt and equity fundraising services, fulfillment, and up-listing advice to a select group of small and mid-sized enterprises. It's financial expertise and decades of collective experience position it to be a difference-maker for clients, no matter the assignment or mandate.

To learn more about services and impact, connect at www.tap-partners.com or info@tap-partners.com.

Stu Opperman
TAP Financial Partners
+1 954-815-2303
stu@impactplayers.com
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/612909550 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.